Business

The Japan Patent Office has allowed JP Application No. 2014-515967 which covers Neurelis’ NRL-1 intranasal diazepam formulation, the company said. In January 2017, Neurelis received Fast Track designation from the US FDA for NRL-1, which… Read more . . .

Bayer has launched a line of saline nasal sprays for children aged 6 months and older in the US, the company said. The products, which include hydraSense Ultra-Gentle Nasal Mist, hydraSense Nasal Care Single-Use Vials… Read more . . .

Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano’s intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services… Read more . . .

Savara has announced that it will develop its Molgradex inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and plans to initiate a Phase 2a trial for that indication in… Read more . . .

Sunovion has announced the US launch of Seebri Neohaler glycopyrrolate DPI for the treatment of COPD. Seebri Neohaler was approved by the FDA in October 2015. Sunovion acquired US rights to Seebri Neohaler, along with… Read more . . .

Amneal Pharmaceuticals and Impax Laboratories have announced that the companies will merge, with the new company to be called Amneal Pharmaceuticals, Inc. The merger is expected to be complete by mid-2018. OINDPs marketed by Amneal… Read more . . .

Aegis Therapeutics says that it has developed an intranasal hydromorphone for the treatment of acute pain and is making the formulation available for license. According to the company, the formulation, which is based on the… Read more . . .

Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza… Read more . . .

Galen US has acquired US rights to Alexza Pharmaceuticals’ Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use… Read more . . .